Registrations
Moderators: I. Boukovinas (GR), G.Douridas (GR)
08.30-08.50 Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors, Claudin-18.2 (CLDN18.2) or HER2 Inhibitors? I. Souglakos (GR)
08.50-09.00 Discussion
Moderators: Η. Gogas (GR), K. Linos (US)
09.00-09.20 mRNA Vaccines – Why Does this Work in melanoma and Ηow is it Applicable to other tumors? V. Karantza (US)
09.20-09.30 Discussion
(1) Peri-operative therapy in NSCLC
Moderators: F.I. Dimitrakopoulos (GR), P. Tomos (GR)
Presenter 1: Case 1 P. Economopoulou (GR)
Presenter 2: Case 2 K. Papagiannopoulos (UK)
Presenter 3: Case 3 O. Sismanidou (GR)
E. Panagiotidis (GR), Α. Kotsakis (GR), P. Economopoulou (GR), K. Papagiannopoulos (UK), K. Iliadis (GR), E. Gkika (DE), I. Georgakopoulos (GR), E. Tsaroucha (GR)
(2) PSMA-positive mCRPC: How to define the sequence of the Treatment (60 min)
Moderators: K. Koutsoukos (GR), P. Tsantoulis (SUI)
Presenter 1: Case 1 A. Andrikopoulou (GR)
Presenter 2: Case 2 I. Binas (GR)
C.Markellos (GR), E.Skoura (GR), P.Skarlos (GR)
Moderators: A. Nikolaidi (GR), M. Liontos (GR)
PARPi for all in front line ovarian cancer? R. Zakopoulou (GR)
Moderators: A. Kotsakis (GR), F.I. Dimitrakopoulos (GR)
12.30-12.50 PD-L1 <1%: Is this the Place for CTLA-4 Inhibition in Lung Cancer? I. Mountzios (GR)
12.50-13.10 STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? S. Gennatas (UK)
13.10-13.30 ADCs: The New Emperor or the Emperor’s New Clothes? D. Papadatos-Pastos (UK)
13.30-13.50 SCLC: Where we stand and what will be the future therapeutic evolution? A. Kyriazoglou (GR)
13.50-14.10 Discussion
Moderators: I. Souglakos (GR), I. Athanasiadis (GR)
15.10-15.30 Short-Course vs. Long-Course Neoadjuvant Radiation Therapy in Rectal Cancer and strategies for organ preserving and quality of life C. Christopoulos (FR)
15.30-15.40 Q&A
15.40-16.00 New Frontiers for Immunotherapy in Hepatocellular Carcinoma D. Papamichael (CY)
16.00-16.10 Q&A
Moderators: E. Lianidou (GR), P. Kosmidis (GR)
Detecting cancer early with molecular tests N. Papadopoulos (US)
Moderators: G. Vasmatzis (US), V. Anagnostou (US)
Presenter: 2 cases G. Vasmatzis
Presenter: 2 cases V. Anagnostou (US) & K. Karaindrou (US)
Presenter: 1 case O. Sismanidou (GR)
Moderators: Ch. Christodoulou (GR), T. Mamounas (US)
Presenter 1: Neoadjuvant treatment in HR +/HER2- breast cancer A. Papatheodoridi (GR)
Presenter 2: Managing the Patient with High-Risk gBRCA-Mutated HR+/HER2- Early-Stage Breast Cancer T. Mamounas (US)
V.Barbounis (GR), S. Douvetzemis (GR), T. Mamounas (US), G. Nasioulas (GR)
Moderators: E. Lianos (GR), Ph. Koinis (GR)
19.10-19.30 Best treatment upfront in urothelial cancer A. Drakakis (US)
19.30-19.40 Q&A
19.40-20.00 Treatment of Special renal cancer histotypes D. Dalianis (GR)
20.00-20.10 Q&A
Moderators: A. Zygogianni (GR), I. Athanasiadis (GR)
08.50-09.10 New Developments in Locoregional Therapy After Neoadjuvant Chemotherapy T. Mamounas (US)
09.10-09.20 Q&A
09.20-09.40 The Evolving Tool Box in Advanced HR+/HER2- Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond V. Kaklamanis (US)
09.40-09.50 Q&A
09.50-10.10 Immunotherapy in breast cancer: where we are? M. Ignatiadis (ΒΕ)
10.10-10.20 Q&A
Moderators: V. Sioulas (GR), A. Koutras (GR)
10.20-10.40 Precision Oncology: Implementation and new drug development A. Tsimberidou (US)
10.40-10.50 Q&A
10.50-11.10 Cervical Cancer is a Preventable Disease: State of the Art of screening and Vaccination and Future Challenges Th. Agorastos (GR)
11.10-11.20 Discussion
Moderators: N. Papadopoulos (US), L. Tsimberidou (US)
11.50-12.10 Is ctDNA Ready for Prime Time for the Detection of Minimal/ Molecular Residual Disease? M. Liu (US)
12.10-12.20 Q&A
12.20-12.40 The transformative impact of AI in a digital pathology lab K. Linos (US)
12.40-12.50 Q&A
12.50-13.10 Synthetic Lethality: The possibility of developing new strategies in the future S. Linardopoulos (UK)
13.10-13.20 Q&A
Moderators: P. Anastasiadis (US), A. Angeli (GR)
Oncology trends in Pharma S. Stergiopoulos (GR)
Moderator: A. Koumarianou (GR)
Long-term survival benefit of IO combinations. The example of HCC and BTC G. Papaxoinis (GR)
Moderators: V. Georgoulias (GR), S. Karagiannis (UK)
Turning Cold Tumors Hot G. Coukos (SUI)
Moderators: S. Karagiannis (UK), I. Pateras (GR)
16.30-16.50 Hepatic metabolism and the systemic host response to tumours D. Anastasiou (UK)
16.50-17.00 Q&A
17.00-17.20 Monoclonal antibodies for the treatment of solid tumours: insights from studying the circulating and tumour-resident immune response S. Karagiannis (UK)
17.20-17.30 Q&A
Moderators: P. Christopoulos (DE), G. Carystinos (GR), G. Kapetanakis (GR)
18.00-18.50 Initiatives of EU in rare cancers (Grants from EU) I. Boukovinas (GR)
18.50-19.00 Q&A
19.00-19.20 The French national network dedicated to rare gynecological cancer A. Patrikidou (FR)
19.20-19.30 Q&A
19.30-19.50 Retroperitoneal Sarcoma Surgery in the Modern Era D. Tzanis (FR)
19.50-20.00 Q&A
Moderators: I. Souglakos (GR), P. Anastasiadis (US), A. Digklia (CH)
20.00-20.20 Personalized treatment in resistant tumours G. Vasmatzis (US)
20.20-20.40 MRD in Urothelial Cancer P. Grivas (US)
20.40-20.50 Q&A